 
 
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: GV118819
                                 Compound class: 
                                                            Synthetic organic
                                 
                                    
                                        Comment: Sanfetrinem cilexetil is the orally bioavailable prodrug of sanfetrinem [1]. It is under clinical development as a treatment for tuberculosis (TB).
                                    
                                 | 
 | |||||||||||||||||||||||||||||||||||
| No information available. | 
| Summary of Clinical Use  | 
| Sanfetrinem cilexetil was developed by GlaxoSmithKline in the 1990s and progressed to clinical evaluation as a treatment for bacterial infections of the upper respiratory tract. Its development was halted based on commercial considerations. More recently, drug repurposing efforts have identified the potential of sanfetrinem cilexetil as a treatment for TB [2]. The drug has completed a Phase 2 trial to evaluate safety, tolerability, pharmacokinetics, and early bactericidal activity (EBA) in adult participants with rifampicin-sensitive pulmonary TB (NCT05388448). | 
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References | 
| NCT05388448 | EBA, Safety and Tolerability of Sanfetrinem Cilexetil | Phase 2 Interventional | TASK Applied Science | ||